LENZ Therapeutics, Inc.
LENZ- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001815776
No open-market purchases or sales by LENZ Therapeutics, Inc. insiders were filed in the last 90 days; 145 institutions reported holding it in 13F filings for Q2 2026, worth $197.3M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, 0 vs. previous quarter
- 145
- 13F valueReported value at the end of Q2 2026
- $197.3M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding LENZ, Q2 2026
No superinvestor reported holding LENZ at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by LENZ Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 (view filing) | Mar 27 | 3 days | George Jeffrey P.Director | PPurchase | +5.59K | $8.92 | +$49.9K | New position5.59K after | |
| Mar 30, 2026 (view filing) | Mar 27 | 3 days | Schimmelpennink Evert B.President, CEO and Secretary | PPurchase | +28.1K | $8.95 | +$251.4K | +57.1%77.3K after | |
| Mar 30, 2026 (view filing) | Mar 27 | 3 days | Chevallard Daniel R.Chief Financial Officer | PPurchase | +7.50K | $8.57 | +$64.3K | +139.2%12.9K after | |
| Nov 19, 2025 (view filing) | Nov 17 | 2 days | Olsson ShawnChief Commercial Officer | SSale | −10.0K | $26.10 | −$261.0K | −67.9%4.73K after | 2 lots10b5-1 |
| Nov 10, 2025 (view filing) | Nov 7 | 3 days | McCollum James WDirector | PPurchase | +10.5K | $22.79 | +$239.3K | New position10.5K after | |
| Nov 7, 2025 (view filing) | Nov 7 | Same day | Chevallard Daniel R.Chief Financial Officer | PPurchase | +2.20K | $22.76 | +$50.0K | +68.9%5.39K after | 2 lots |
| Oct 2, 2025 (view filing)4:40 PM ET | Sep 30 | 2 days | Versant Venture Capital VI, L.P. and 8 others10% Owner | SSale | −132.9K | $46.01 | −$6.12M | −11.2%1.05M after | 3 lots |
| Oct 2, 2025 (view filing)4:40 PM ET | Sep 30 | 2 days | Versant Venture Capital VI, L.P. and 8 others10% Owner | SSale | −92.0K | $46.01 | −$4.23M | −10.7%764.1K after | 3 lots |
| Sep 22, 2025 (view filing)4:23 PM ET | Sep 18 | 4 days | Versant Venture Capital VI, L.P. and 8 others10% Owner | SSale | −90.7K | $42.23 | −$3.83M | −7.1%1.18M after | 3 lots |
| Sep 22, 2025 (view filing)4:23 PM ET | Sep 18 | 4 days | Versant Venture Capital VI, L.P. and 8 others10% Owner | SSale | −44.6K | $42.23 | −$1.89M | −5.0%856.2K after | 3 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in LENZ Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 4,178,823 | $23.7M | 0.21% | 00.0% | Unchanged |
| Falcon Edge Capital, LP | 3,612,211 | $20.5M | 0.33% | 00.0% | Unchanged |
| FMR LLC | 3,558,905 | $20.2M | 0.00% | −38,879−1.1% | Reduced |
| Versant Venture Management, LLC | 2,656,888 | $15.1M | 9.28% | 00.0% | Unchanged |
| BlackRock, Inc. | 2,292,121 | $13.0M | 0.00% | +315,298+15.9% | Added |
| Squarepoint Ops LLC | 1,747,096 | $9.92M | 0.02% | +240,597+16.0% | Added |
| Standard Life Aberdeen plc | 1,547,883 | $8.79M | 0.01% | +391,722+33.9% | Added |
| Millennium Management LLC | 1,508,478 | $8.57M | 0.01% | +639,221+73.5% | Added |
| Vanguard Capital Management LLC | 1,097,755 | $6.24M | 0.00% | +56,567+5.4% | Added |
| 72 Investment Holdings, LLC | 1,017,751 | $5.78M | 11.57% | 00.0% | Unchanged |